{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:00:27Z","timestamp":1784548827187,"version":"3.55.0"},"reference-count":34,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Roxadustat (Rox), a hypoxia-inducible factor (HIF) stabilizer, is now available for the treatment of anemia in hemodialysis (HD) patients. To investigate hematopoietic effect and iron metabolism, this study involved 30 HD patients who were initially treated with darbepoetin (DA), a conventional erythropoietin-stimulating agent, and then switched to Rox. We measured erythrocyte, reticulocyte indices, and iron-related factors at every HD during the first two weeks after the treatment switch (Days 0\u201314) and again on Days 21 and 28. We measured erythropoietin (EPO) concentration every week and examined their changes from Day-0 values. The same variables were measured in 15 HD patients who continued DA at every HD for one week. Iron-related factors were also measured on Days 14 and 28. In the Rox group, hepcidin significantly decreased from Day 2. The reticulocyte hemoglobin content (CHr) significantly increased on Day 4, but decreased with a significant increase in reticulocyte count from Day 7. Log10(serum ferritin) significantly decreased after Day 11. Log10(EPO concentration) was lower at all time points. Compared with the DA group, the Rox group showed significant differences in all variables except CHr. These results suggest that Rox improves hematopoiesis and iron metabolism early after administration independent of EPO concentration.<\/jats:p>","DOI":"10.3390\/ijms21197153","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T08:02:58Z","timestamp":1601280178000},"page":"7153","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["A Hypoxia-Inducible Factor Stabilizer Improves Hematopoiesis and Iron Metabolism Early after Administration to Treat Anemia in Hemodialysis Patients"],"prefix":"10.3390","volume":"21","author":[{"given":"Chie","family":"Ogawa","sequence":"first","affiliation":[{"name":"Maeda Institute of Renal Research, 6F-1-403 Kosugi-cho, Nakahara-ku, Kawasaki 211-0063, Japan"},{"name":"Biomarker Society, INC, 6F-1-403 Kosugi-cho, Nakahara-ku, Kawasaki 211-0063, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Biomarker Society, INC, 6F-1-403 Kosugi-cho, Nakahara-ku, Kawasaki 211-0063, Japan"},{"name":"Department of Blood Purification, Tokyo Women\u2019s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohisa","family":"Tomosugi","sequence":"additional","affiliation":[{"name":"Biomarker Society, INC, 6F-1-403 Kosugi-cho, Nakahara-ku, Kawasaki 211-0063, Japan"},{"name":"Division of Systems Bioscience for Drug Discovery Project Research Center, Medical Research Institute, Kanazawa Medical University, 1-1 Daigaku, Uchinada-machi, Kahoku-gun, Ishikawa 920-0293, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunimi","family":"Maeda","sequence":"additional","affiliation":[{"name":"Maeda Institute of Renal Research, 6F-1-403 Kosugi-cho, Nakahara-ku, Kawasaki 211-0063, Japan"},{"name":"Biomarker Society, INC, 6F-1-403 Kosugi-cho, Nakahara-ku, Kawasaki 211-0063, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1492-7535.2005.01129.x","article-title":"Chronic viral hepatitis in hemodialysis patients","volume":"9","author":"Tang","year":"2005","journal-title":"Hemodial. Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000167425","article-title":"Risk of iron overload and \u2018hemochromatosis allele(s)\u2019 in patients on maintenance hemodialysis","volume":"7","author":"Meloni","year":"1987","journal-title":"Am. J. Nephrol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0272-6386(88)80066-0","article-title":"Noninvasive assessment of skin iron content in hemodialysis patients. An index of parenchymal tissue iron content?","volume":"12","author":"Friedlaender","year":"1988","journal-title":"Am. J. Kidney Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7580","DOI":"10.1073\/pnas.82.22.7580","article-title":"Cloning and expression of the human erythropoietin gene","volume":"82","author":"Lin","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1093\/ndt\/gfr697","article-title":"Systematic review of the impact of erythropoiesis\u2012stimulating agents on fatigue in dialysis patients","volume":"27","author":"Johansen","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2215\/CJN.04950908","article-title":"Erythropoietin Therapy, Hemoglobin Targets, and Quality of Life in Healthy Hemodialysis Patients: A Randomized Trial","volume":"4","author":"Foley","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_7","first-page":"76","article-title":"Effects of erythropoietin on blood pressure","volume":"18","author":"Raine","year":"1991","journal-title":"Am. J. Kidney Dis."},{"key":"ref_8","first-page":"164","article-title":"Angiotensin-converting enzyme inhibitors are associated with the need for increased recombinant human erythropoietin maintenance doses in hemodialysis patients","volume":"77","author":"Matsumura","year":"1997","journal-title":"Risks Card. Dis. Dial. Patients Study Group"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/ndt\/17.suppl_11.39","article-title":"Erythropoietin resistance: The role of inflammation and pro-inflammatory cytokines","volume":"17","author":"Macdougall","year":"2002","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1097\/01.ASN.0000140219.28618.9F","article-title":"Canadian PRCA Focus Group: Anti\u2012erythropoietin antibody\u2012mediated pure red cell aplasia after treatment with recombinant erythropoietin products: Recommendations for minimization of risk","volume":"15","author":"Cournoyer","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/ndt\/gfl727","article-title":"Antibody-mediated acquired pure red cell aplasia (PRCA) after treatment with darbepoetin","volume":"22","author":"Howman","year":"2007","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/j.1523-1755.2005.00532.x","article-title":"Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin","volume":"68","author":"Fishbane","year":"2005","journal-title":"Kidney Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1093\/ndt\/gfs368","article-title":"Association of malnutrition\u2013inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients","volume":"28","author":"Rattanasompattikul","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_14","first-page":"5447","article-title":"A Nuclear Factor Induced by Hypoxia via De Novo Protein Synthesis Binds to the Human Erythropoietin Gene Enhancer at a Site Required for Transcriptional Activation","volume":"12","author":"Semenza","year":"1992","journal-title":"Mol. Cell Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1172\/JCI31370","article-title":"Regulation of Iron Homeostasis by the Hypoxia-Inducible Transcription Factors (HIFs)","volume":"117","author":"Peyssonnaux","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1172\/JCI63924","article-title":"Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis","volume":"122","author":"Liu","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3324\/haematol.2011.056119","article-title":"Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis","volume":"97","author":"Mastrogiannaki","year":"2012","journal-title":"Haematologica"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1182\/blood-2011-01-258467","article-title":"Hepcidin and iron regulation, 10 years later","volume":"117","author":"Ganz","year":"2011","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ejh.12067","article-title":"Greater potency of darbepoetin-\u03b1 than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients","volume":"90","author":"Shoji","year":"2013","journal-title":"Eur. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study","volume":"67","author":"Provenzano","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","article-title":"Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients","volume":"30","author":"Besarab","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1182\/blood-2005-10-4043","article-title":"Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System","volume":"108","author":"Tomosugi","year":"2006","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI200420945","article-title":"IL-6 mediates ypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin","volume":"113","author":"Nemeth","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.freeradbiomed.2018.07.003","article-title":"Erythropoietic regulators of iron metabolism","volume":"133","author":"Ganz","year":"2019","journal-title":"Free Radic. Biol. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/ki.1997.323","article-title":"Reticulocyte Hemoglobin Content in the Evaluation of Iron Status of Hemodialysis Patients","volume":"52","author":"Fishbane","year":"1997","journal-title":"Kidney Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1182\/blood.V83.10.3100.3100","article-title":"Reticulocyte hemoglobin content (CHr): Early indicator of iron deficiency and response to therapy","volume":"83","author":"Brugnara","year":"1994","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"20055","DOI":"10.1074\/jbc.272.32.20055","article-title":"Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1","volume":"272","author":"Rolfs","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_28","first-page":"6","article-title":"Clinical evaluation of iron deficiency","volume":"19","author":"Cook","year":"1982","journal-title":"Semin. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ogawa, C., Tsuchiya, K., Tomosugi, N., Kanda, F., Maeda, K., and Maeda, T. (2017). Low Levels of Serum Ferritin and Moderate Transferrin Saturation Lead to Adequate Hemoglobin Levels in Hemodialysis Patients, Retrospective Observational Study. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0179608"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1159\/000312381","article-title":"Determinants of Hepcidin in Patients on Maintenance Hemodialysis: Role of Inflammation","volume":"31","author":"Kuragano","year":"2010","journal-title":"Am. J. Nephrol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.1074\/jbc.272.9.5375","article-title":"Hypoxia-inducible factor-1 Mediates Transcriptional Activation of the Heme oxygenase-1 Gene in Response to Hypoxia","volume":"272","author":"Lee","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"21048","DOI":"10.1074\/jbc.M000636200","article-title":"Role of Hypoxia-inducible Factor-1 in Transcriptional Activation of Ceruloplasmin by Iron Deficiency","volume":"275","author":"Mukhopadhyay","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1053\/j.gastro.2011.03.007","article-title":"Hypoxia-inducible factor-2\u03b1 mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice","volume":"140","author":"Taylor","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"24147","DOI":"10.1074\/jbc.274.34.24147","article-title":"Identification of a Hypoxia Response Element in the Transferrin Receptor Gene","volume":"274","author":"Lok","year":"1999","journal-title":"J. Biol. Chem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/19\/7153\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:14:26Z","timestamp":1760177666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/19\/7153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,28]]},"references-count":34,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["ijms21197153"],"URL":"https:\/\/doi.org\/10.3390\/ijms21197153","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,28]]}}}